newsfilter
← Latest News
Business Wire·

Sensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer

SRTS
  • Sensus Healthcare reported Q4 2025 revenues of $4.9 million and full-year 2025 revenues of $27.5 million, with net losses of $3.2 million for the quarter and $7.7 million for the year.
  • The company shipped 14 SRT systems in Q4 2025, including 8 in the U.S. and 6 internationally, with no shipments to its historically largest customer during the period.
  • Full-year 2025 shipments totaled 70 SRT systems, comprising 56 in the U.S. and 14 internationally.
  • The 2026 CMS Physician Fee Schedule Final Rule provides a 300% per-fraction reimbursement increase for SRT delivery codes effective January 1, 2026.
  • The Fair Deal Agreement (FDA) program expanded to 18 active sites and 10 pending sites, with 11,411 treatments delivered to 922 patients in 2025 compared to 1,367 treatments for 264 patients in 2024.
  • Management expects sequential revenue growth in Q1 2026 without contribution from the largest customer and aims for full-year 2026 profitability.
  • The company ended 2025 with $22.1 million in cash and cash equivalents and no outstanding debt.
  • Adjusted EBITDA was negative $3.0 million for Q4 2025 and negative $9.6 million for the full year 2025.
  • Research and development expenses increased to $7.8 million for 2025 due to lobbying costs, increased headcount, and next-generation product development.
  • A conference call to discuss these results is scheduled for 4:30 p.m. Eastern time on February 12, 2026.